// App-Quantinova.ai

PO‐055 : A phase III efficacy and safety study of the proposed rituximab biosimilar GP2013 versus rituximab in 629 patients with previously untreated advanced follicular lymphoma

Researchers

Presenter

  • W Jurczak

Principal Investigators

  • KS Govindbabu

  • E Munhoz

  • M-A Echeveste

  • P Giri

  • N Castro

  • J Pereira

  • A Luiza

  • S Alexeev

  • E Kanfer

Medical Centers

  • Malopolskie Centrum Medyczne, Krakow, Poland

  • Imperial College, London, United Kingdom

Locations

  • Poland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Rituximab biosimilar

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Vincristine

  • Prednisone

  • Rituximab

  • GP2013

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Pharmacodynamics

  • Double Blind/Blinded

  • Prospective

  • Controlled

  • Parallel Group

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved